WORKING TOGETHER TO MAKE MEDICAL CANNABIS MORE ACCESSIBLE AS A MEDICINE in EUROPE
Today Dr. Bernhard Babel and Neil Smith share their knowledge and views on how to make Cannabis-based Medicines more accessible in Europe at CBD Live. CBD Live is one of the most important CBD and Medicinal Cannabis events in Europe.
In addition, Dr Anthony Ordman of the Integro Medical Clinics participates in the panel discussion. Dr Ordman, a Pain Management Specialist, is one of the UK’s leading experts on treatment with Cannabis-based Medicines.
Eurox Pharma are delighted to announce the addition of cannabis industry heavy-weight Chuck Rifici to their board
Rifici is currently Executive Chairman of Feather Company and co-founder of Canopy Growth Corporation and the Auxly Cannabis Group. He previously served on the board of directors of Aurora Cannabis Inc., The Supreme Cannabis Company, Origin House and Meta Growth Corp. He joins Amy Peckham, CEO of Etain Health, USA, and Michael Reckeweg, Chairman of Dr. Reckeweg & Co, on the advisory board.
Eurox was founded in 2019 by its’ CEO’s ex-Deutsche Bank Senior Executive, Neil Smith, Bernhard Babel, ex- Partner at McKinsey & Co and David Reckeweg-Lecompte, CEO of Dr Reckeweg & Co, a 75 year old pharmaceutical company producing plant-based medicines in Germany.
Eurox will produce a broad range of cannabis-based pharmaceuticals and products in Bensheim, Germany. The 10,000 sq meters manufacturing plant was certified as a fully GMP facility in October 2020. At full capacity it will have potential to manufacture 50 tonnes of product.
Eurox produces premium cannabis products, in accordance with the highest German and EU pharmaceutical quality and safety standards. The organisation is backed by cutting-edge research and together with their partners has a global distribution network.
Commercial production will commence in Q2 2021. In addition to its’ German operations Eurox is a founding partner in the cannabis medicines based Integro Medical Clinics Limited in the UK with leading British pharmaceutical company IPS.
“We are absolutely delighted to welcome Chuck, an industry legend to our organisation. The experience and advice he will be able to offer us as a new player in the European cannabis pharmaceutical market will be invaluable. It is our goal to see Eurox as a major independent player in this market within the next 3-5 years. The market has massive growth potential which we intend to embrace and exploit.”
co-CEO Neil Smith
For further information and interviews/comments please contact Jessica Smith, Jessica.Smith@eurox-group.de.